Company intelligence / Profile preview

Finlay Vaccine Institute

Ownership: Private
Employees: ~970
Development stage: Other

Overview

The institute has developed multiple approved vaccines, including those against meningococcal disease and leptospirosis. Its COVID vaccine candidates, notably Soberana series (Soberana 01, Soberana 02, Soberana Plus), have shown high efficacy (>90%) in clinical trials. The heterologous schedule with SOBERANA Plus demonstrated strong immunogenicity and safety profiles with long-lasting antibody responses[5][6]. Technology transfer agreements have enabled international production of its COVID vaccines.

Therapeutic areas: Infectious Diseases
Modalities: Prophylactic vaccinesGenetically engineered subunit vaccines
Industry: Biotech

Drug pipeline

15 assets

PastoCovac

14 more assets in the full pipeline.

Partnerships

Pasteur Institute of Iran (technology transfer for Soberana 02/Soberana Plus)BioCubaFarma group collaborations

Beyond the preview

Go deeper on Finlay Vaccine Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Finlay Vaccine Institute.